Feline Immunodeficiency Virus (FIV)

Jericho is developing a new therapeutic drug for FIV infection in cats, working toward a New Animal Drug Application (NADA) with the FDA. Our ongoing studies indicate that Jericho’s small molecule drug candidate can reduce FIV virus levels in chronically-infected cats for many months in the absence of continuing treatment. Extensive testing also indicates that the drug candidate has a good safety profile. Reducing FIV viral loads will help protect damage to cats’ immune systems.

  • As with HIV, FIV infects immune cells of of the cat. While the virus may not cause immediate symptoms, the cat’s immune system will weaken over time.
  • Approximately 2-3% of cats in the United States are infected with FIV. The virus is typically spread through bites (unlike HIV), so it is especially prevalent among aggressive male cats that live outdoors.
  • FIV diagnostic tests may not be able to distinguish vaccinated cats from infected cats. While vaccines for FIV have certainly helped to reduce the frequency of infections, FDA-approved antiretroviral drugs for cats that become infected are currently not available.

Symptoms of FIV may include:

  • Recurrent illnesses
  • Poor coat condition
  • Persistent fever
  • Loss of appetite
  • Swollen lymph nodes
  • Inflammation of the gums and mouth
  • Chronic infection of the eyes, skin, bladder, or lungs
  • Persistent diarrhea
  • Progressive weight loss

Source: https://emedicine.medscape.com/article/246031-overview